This interview will focus on the current treatment landscape and the prescribing patterns of Lexicon's dual SGLT1 and SGLT2 inhibitor Inpefa (sotagliflozin) in patients with heart failure
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
2025 Q1 #3 Speaking with a Cardiologist who has experience treating heart failure patients to discuss the standard of care and the use of Inpefa (sotagliflozin).
Ticker(s): LXRXWho's the expert?
Institution: Columbia University
-
Sees patients for hypertension, valvular disease, congestive heart failure, pulmonary artery hypertension, ischemic heart disease, preventive cardiology, and arrhythmias.
-
sees 100 patients per week and at 1/3 or 33 patients or obese/overweight and at risk for mace
-
Research Interests are in lipids and metabolism, hypertension, nephropathy post-cardiac catheterization, and the occluded artery trial.
familiar with both invasive (cardiac catheterization and electrophysiology) and non-invasive procedures (echocardiography and stress testing)
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
